Manipulating TLR Signaling Increases the Anti-tumor T Cell Response Induced by Viral Cancer Therapies

[1]  H. Atkins,et al.  Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity , 2015, Nature Medicine.

[2]  J. Bertin,et al.  Toll-like Receptor 3-mediated Necrosis via TRIF, RIP3, and MLKL* , 2013, The Journal of Biological Chemistry.

[3]  M. Bloomston,et al.  Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer , 2013, Nature Medicine.

[4]  D. Bartlett,et al.  Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  S. Thorne,et al.  Regulating cytokine function enhances safety and activity of genetic cancer therapies. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  N. Senzer,et al.  OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[8]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[9]  Steven A. Rosenberg,et al.  Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know , 2011, Nature Reviews Clinical Oncology.

[10]  S. Steinberg,et al.  Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.

[11]  Charles Schmidt.  Amgen spikes interest in live virus vaccines for hard-to-treat cancers , 2011, Nature Biotechnology.

[12]  J. Engh,et al.  Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Peter O. Krutzik,et al.  Alternate mechanisms of initial pattern recognition drive differential immune responses to related poxviruses. , 2010, Cell host & microbe.

[14]  Edward R. Kastenhuber,et al.  Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-α and IFN-γ dependent manners , 2010, Cancer Immunology, Immunotherapy.

[15]  T. Seya,et al.  The extrinsic RNA-sensing pathway for adjuvant immunotherapy of cancer , 2009, Cancer Immunology, Immunotherapy.

[16]  D. Sze,et al.  Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. , 2008, The Lancet. Oncology.

[17]  Hideo Negishi,et al.  Regulation of innate immune responses by DAI (DLM-1/ZBP1) and other DNA-sensing molecules , 2008, Proceedings of the National Academy of Sciences.

[18]  R. Steinman,et al.  The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine , 2008, Proceedings of the National Academy of Sciences.

[19]  K. Honda,et al.  DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response , 2007, Nature.

[20]  C. June,et al.  Adoptive T cell therapy for cancer in the clinic. , 2007, The Journal of clinical investigation.

[21]  Edgar Schmitt,et al.  Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. , 2006, Blood.

[22]  H. Kaufman,et al.  Poxvirus vaccines for cancer and HIV therapy , 2004, Expert opinion on biological therapy.

[23]  P. Jahrling,et al.  Evaluation in Nonhuman Primates of Vaccines against Ebola Virus , 2002, Emerging infectious diseases.

[24]  I. Tannock,et al.  A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.

[25]  M. Gulley,et al.  A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  M. Gulley,et al.  Erratum: A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer (Clinical Cancer Research (2000) 6 (798-806)) , 2000 .

[27]  F. McCormick,et al.  ONYX-015: Clinical data are encouraging , 1998, Nature Medicine.

[28]  S. Hoffman,et al.  Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. , 1998, The Journal of infectious diseases.

[29]  B. Moss,et al.  Compact, synthetic, vaccinia virus early/late promoter for protein expression. , 1997, BioTechniques.

[30]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.